Actively Recruiting
Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2024-02-15
45
Participants Needed
1
Research Sites
512 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is aimed to evaluate the effects of intraovarian injection of autologous Platelet-enriched Autologous Plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue.
CONDITIONS
Official Title
Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Request for cryopreserved ovarian tissue transplantation
- Premature ovarian failure or irregular menstrual cycles
- Negative tests for HIV, HBV, HCV, and Treponema pallidum
- Negative PAP test
- Oncological authorization
- No neoplastic contamination in the cryopreserved ovarian tissue
- Informed consent provided
You will not qualify if you...
- Neoplastic contamination in cryopreserved ovarian tissue
- History of endometriosis
- Untreated endocrinological disorders (uncompensated thyroid dysfunction, type 1 or type 2 diabetes)
- Body mass index greater than 30 kg/m2
- Circulating platelet level below 150,000 per mm3
- Bacterial infection
- Current use of anticoagulant medications
- Bleeding diathesis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Diego Raimondo
Bologna, BO, Italy, 40138
Actively Recruiting
Research Team
D
Diego Raimondo, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here